Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03942029 · ClinicalTrials.gov registry record · Phase 1
A Drug Interaction Study of LY3154207 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03942029 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 36 participants.
The verdict
NCT03942029, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn more about the safety and side effects of LY3154207 and fluconazole (anti-fungal medication), when taken together by healthy participants. The study will last from nine to 11 weeks for each participant.
Interventions
- DRUG Placebo
- DRUG Fluconazole Tablet
- DRUG LY3154207 Capsule
- DRUG LY3154207 Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-06-21 |
| Est. Completion | 2019-12-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03942029
The ClinicalTrials.gov registry entry for NCT03942029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03942029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03942029 about?
NCT03942029 is a clinical study titled "A Drug Interaction Study of LY3154207 in Healthy Participants". The main purpose of this study is to learn more about the safety and side effects of LY3154207 and fluconazole (anti-fungal medication), when taken together by healthy participants. The study will last from nine to 11 weeks for each participant.
What is the current status of trial NCT03942029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2019-06-21. Estimated completion is 2019-12-28.
What interventions are being tested in trial NCT03942029?
The interventions under investigation include: Placebo (DRUG), Fluconazole Tablet (DRUG), LY3154207 Capsule (DRUG), LY3154207 Tablet (DRUG).
Who is sponsoring clinical trial NCT03942029?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.